Lupin gains on signing promotional agreement with Exeltis
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 901.65, up by 13.55 points or 1.53% from its previous closing of Rs. 888.10 on the BSE.
The scrip opened at Rs. 887.00 and has touched a high and low of Rs. 906.65 and Rs. 887.00 respectively. So far 19736 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 854.00 on 20-Dec-2021.
Last one week high and low of the scrip stood at Rs. 933.00 and Rs. 882.00 respectively. The current market cap of the company is Rs. 40879.99 crore.
The promoters holding in the company stood at 46.81%, while Institutions and Non-Institutions held 40.39% and 12.79% respectively.
Lupin Pharmaceuticals Inc. (Lupin) and Exeltis USA Inc. have entered into promotional agreement for Exeltis to promote SOLOSEC along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients.
SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the U.S.).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
